{"id":26255,"date":"2023-12-15T22:37:19","date_gmt":"2023-12-15T17:07:19","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=26255"},"modified":"2024-09-17T16:56:33","modified_gmt":"2024-09-17T11:26:33","slug":"golcadomide-delivers-promising-result-in-large-b-cell-lymphomas","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/golcadomide-delivers-promising-result-in-large-b-cell-lymphomas","title":{"rendered":"Harmony in Treatment: GOLCA (golcadomide) Reveals Favorable Safety Profile and Seamless Integration with R-CHOP for Untreated Aggressive B-Cell Lymphoma"},"content":{"rendered":"\n
Date of Abstract presentation<\/td>11th December 2023<\/td><\/tr>
Indications<\/td>Aggressive B-cell lymphoma (a-BCL)<\/td><\/tr>
Abstract Number<\/td>4459<\/td><\/tr>
Abstract type<\/td>Poster<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Approximately 40% of patients diagnosed with diffuse large B-cell lymphoma (DLBCL) experience relapse following initial treatment with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemo-immunotherapy. The CELMoD agents, exemplified by GOLCA, demonstrate potent capabilities in degrading target proteins Ikaros\/Aiolos, leading to a multifaceted impact characterized by antiproliferative, apoptotic, and immunomodulatory activities. As per the results presented at the ASH 2023 conference, there were 71 patients evaluated for efficacy, and the overall response rate (ORR) reported in the patients at the end of treatment was 84.5%, <\/strong>with 87.9% of patients in the (dose levels) DL1 arm achieving a complete metabolic response (CMR) compared to 63.6% in the DL-1 arm. Attaining minimal residual disease negativity at the end of treatment was observed in 93% of patients who received 0.4 mg of golcadomide in combination with R-CHOP, surpassing the rate of 70% observed in patients treated with 0.2 mg of golcadomide alongside R-CHOP.<\/p>\n\n\n\n

Within the safety population, Grade 3\/4 treatment-emergent adverse events (TEAEs) were predominantly hematologic, with neutropenia (89.7%), thrombocytopenia (42.3%), and anemia (32.1%) being the most common. Furthermore, febrile neutropenia of any grade was observed in 21.8% of patients. Importantly, the median relative dose intensity of crucial components in the R-CHOP regimen was consistently upheld at over 90%, indicating a robust and well-tolerated treatment approach. This novel approach holds promise in addressing the challenges of relapse in DLBCL, presenting a potential paradigm shift in the therapeutic landscape.<\/p>\n\n\n\n

 KOL Insights<\/strong><\/h2>\n\n\n\n

\u201cGolcadomide is a novel, oral CELMoD agent representing one of several compelling assets generated from our differentiated targeted protein degradation research platform. \u201cIn the studies being presented at ASH 2023, golcadomide has shown potential warranting further evaluation in patients with first-line and previously treated large B-cell lymphomas. We are encouraged by the growing body of evidence for this purposefully designed lymphoma agent as we continue toward a registrational program.\u201d \u2013Expert Opinion.<\/strong><\/p>\n\n\n\n

Conclusion<\/strong><\/h2>\n\n\n\n

GOLCA exhibited a well-tolerated safety profile, demonstrated favorable compatibility with R-CHOP, and did not impede the administration of curative treatment. Notably, the promising potential observed with golcadomide suggests the need for continued assessment in both first-line and previously treated large B-cell lymphomas.<\/p>\n\n\n\n

Refer to the Related Reports for More In-depth Insights –<\/strong><\/p>\n\n\n\n

\n
\n

Diffuse Large B-cell Lymphoma Market<\/a><\/strong><\/p>\n\n\n\n

Multiple Myeloma Market<\/a><\/strong><\/p>\n\n\n\n

Marginal Zone Lymphoma Market<\/a><\/strong><\/p>\n\n\n\n

Acute Lymphocytic Leukemia (ALL) Market<\/a><\/strong><\/p>\n\n\n\n

Chronic Lymphocytic Leukemia Market<\/a><\/strong><\/p>\n<\/div>\n\n\n\n

\n

Mantle Cell Lymphoma Market<\/a><\/strong><\/p>\n\n\n\n

Hodgkin’s lymphoma Market<\/a><\/strong><\/p>\n\n\n\n

Myelofibrosis Market<\/a><\/strong><\/p>\n\n\n\n

Myelodysplastic Syndrome Market<\/a><\/strong><\/p>\n\n\n\n

Follicular Lymphoma Market<\/a><\/strong><\/p>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Date of Abstract presentation 11th December 2023 Indications Aggressive B-cell lymphoma (a-BCL) Abstract Number 4459 Abstract type Poster Approximately 40% of patients diagnosed with diffuse large B-cell lymphoma (DLBCL) experience relapse following initial treatment with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemo-immunotherapy. The CELMoD agents, exemplified by GOLCA, demonstrate potent capabilities in degrading target […]<\/p>\n","protected":false},"author":6,"featured_media":26301,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[41],"tags":[20413,20004,21525,21534,20617,137,841,927,19005,19118],"industry":[17225],"therapeutic_areas":[17233,17228],"class_list":["post-26255","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-snippets","tag-abstracts","tag-american-society-of-hematology","tag-ash-2023","tag-ash-abstracts","tag-b-cell-lymphoma","tag-cancer","tag-cancer-research","tag-cancer-treatment","tag-diffuse-large-b-cell-lymphoma-2","tag-large-b-cell-lymphoma","industry-pharmaceutical","therapeutic_areas-hematological-disorders","therapeutic_areas-oncology"],"acf":[],"yoast_head":"\nGolcadomide Reveals Promising Result in B-Cell Lymphoma Pts.<\/title>\n<meta name=\"description\" content=\"Golcadomide (GOLCA; CC-99282) Plus R-CHOP in pts with Previously Untreated Aggressive B-Cell Lymphoma delivers Safety and Efficacy Results\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/golcadomide-delivers-promising-result-in-large-b-cell-lymphomas\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Golcadomide Reveals Promising Result in B-Cell Lymphoma Pts.\" \/>\n<meta property=\"og:description\" content=\"Golcadomide (GOLCA; CC-99282) Plus R-CHOP in pts with Previously Untreated Aggressive B-Cell Lymphoma delivers Safety and Efficacy Results\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/golcadomide-delivers-promising-result-in-large-b-cell-lymphomas\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2023-12-15T17:07:19+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-09-17T11:26:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/12\/15223610\/golcadomide-in-large-b-cell-lymphomas.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"800\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Golcadomide Reveals Promising Result in B-Cell Lymphoma Pts.","description":"Golcadomide (GOLCA; CC-99282) Plus R-CHOP in pts with Previously Untreated Aggressive B-Cell Lymphoma delivers Safety and Efficacy Results","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/golcadomide-delivers-promising-result-in-large-b-cell-lymphomas","og_locale":"en_US","og_type":"article","og_title":"Golcadomide Reveals Promising Result in B-Cell Lymphoma Pts.","og_description":"Golcadomide (GOLCA; CC-99282) Plus R-CHOP in pts with Previously Untreated Aggressive B-Cell Lymphoma delivers Safety and Efficacy Results","og_url":"https:\/\/www.delveinsight.com\/blog\/golcadomide-delivers-promising-result-in-large-b-cell-lymphomas","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2023-12-15T17:07:19+00:00","article_modified_time":"2024-09-17T11:26:33+00:00","og_image":[{"width":1200,"height":800,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/12\/15223610\/golcadomide-in-large-b-cell-lymphomas.png","type":"image\/png"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/golcadomide-delivers-promising-result-in-large-b-cell-lymphomas","url":"https:\/\/www.delveinsight.com\/blog\/golcadomide-delivers-promising-result-in-large-b-cell-lymphomas","name":"Golcadomide Reveals Promising Result in B-Cell Lymphoma Pts.","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/golcadomide-delivers-promising-result-in-large-b-cell-lymphomas#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/golcadomide-delivers-promising-result-in-large-b-cell-lymphomas#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/12\/15223610\/golcadomide-in-large-b-cell-lymphomas.png","datePublished":"2023-12-15T17:07:19+00:00","dateModified":"2024-09-17T11:26:33+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/0d96a31a370c143ffdb481d985d7edfd"},"description":"Golcadomide (GOLCA; CC-99282) Plus R-CHOP in pts with Previously Untreated Aggressive B-Cell Lymphoma delivers Safety and Efficacy Results","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/golcadomide-delivers-promising-result-in-large-b-cell-lymphomas"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/golcadomide-delivers-promising-result-in-large-b-cell-lymphomas#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/12\/15223610\/golcadomide-in-large-b-cell-lymphomas.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/12\/15223610\/golcadomide-in-large-b-cell-lymphomas.png","width":1200,"height":800,"caption":"Golcadomide in B-Cell Lymphoma"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/0d96a31a370c143ffdb481d985d7edfd","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/f9314f22b8c5b61d496451e91f32488d2457ecb59283b7b2ad7e82d330b47aba?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/f9314f22b8c5b61d496451e91f32488d2457ecb59283b7b2ad7e82d330b47aba?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/arawat"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/12\/15223610\/golcadomide-in-large-b-cell-lymphomas-300x200.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Snippets - A Small piece of News or Article<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Snippets - A Small piece of News or Article<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Abstracts<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">American Society of Hematology<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">ASH 2023<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">ASH Abstracts<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">B-cell Lymphoma<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Cancer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Cancer research<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Cancer Treatment<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">diffuse large B-cell lymphoma<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Large B-cell Lymphoma<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Abstracts<\/span>","<span class=\"advgb-post-tax-term\">American Society of Hematology<\/span>","<span class=\"advgb-post-tax-term\">ASH 2023<\/span>","<span class=\"advgb-post-tax-term\">ASH Abstracts<\/span>","<span class=\"advgb-post-tax-term\">B-cell Lymphoma<\/span>","<span class=\"advgb-post-tax-term\">Cancer<\/span>","<span class=\"advgb-post-tax-term\">Cancer research<\/span>","<span class=\"advgb-post-tax-term\">Cancer Treatment<\/span>","<span class=\"advgb-post-tax-term\">diffuse large B-cell lymphoma<\/span>","<span class=\"advgb-post-tax-term\">Large B-cell Lymphoma<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 2 years ago","modified":"Updated 2 years ago"},"absolute_dates":{"created":"Posted on Dec 15, 2023","modified":"Updated on Sep 17, 2024"},"absolute_dates_time":{"created":"Posted on Dec 15, 2023 10:37 pm","modified":"Updated on Sep 17, 2024 4:56 pm"},"featured_img_caption":"Golcadomide in B-Cell Lymphoma","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/26255","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=26255"}],"version-history":[{"count":1,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/26255\/revisions"}],"predecessor-version":[{"id":29571,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/26255\/revisions\/29571"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/26301"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=26255"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=26255"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=26255"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=26255"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=26255"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}